Genzyme Genetics enhances diagnostic system:
This article was originally published in Clinica
Executive Summary
Cambridge, Massachusetts-based Genzyme Genetics, a unit of Genzyme General, has expanded its cancer testing services by "significantly stepping up" its flow cytometry programme performed in laboratories in Santa Fe, Mexico. Dr Bruce Davis, associate director for clinical research at Maine Medical Center, will direct staff interpreting test results and providing consultation services to physicians. The company has also compiled a database to assist in the interpretation of complex cases. Physicians will have secure internet access to test results as they become available. Flow cytometry diagnoses leukaemia, lymphoma, multiple myeloma among other cancers, monitors residual levels of disease present in post-treatment patients and is used as an evaluative tool of patients whose treatment is likely to fail.